Cancer therapy based on tumor associated antigens derived from cyclin d1

a technology of cyclin d1 and tumors, applied in the field of cyclin-derived peptides, can solve the problem of not providing precise information as to the use of the antigens transcribed from these genes

Active Publication Date: 2012-02-02
IMMATICS BIOTECHNOLOGIES GMBH
View PDF6 Cites 24 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0026]In a first aspect thereof, the object of the present invention is solved by a peptide consisting of or essentially consisting of an amino acid sequence selected from SEQ ID NO: 1 to SEQ ID NO: 18 for use in the treatment of cancer in a patient, or a combination comprising at least one peptide consisting of or essentially consisting of an amino acid sequence selected from SEQ ID NO: 1 to SEQ ID NO: 18 for use in the treatment of cancer in a patient.

Problems solved by technology

However, the identification of genes overexpressed in tumor tissues or human tumor cell lines, or selectively expressed in such tissues or cell lines, does not provide precise information as to the use of the antigens transcribed from these genes in an immune therapy.
Nevertheless, WO 2005 / 035714 does not describe any advantages regarding a combination treatment using cyclin D1 peptides.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cancer therapy based on tumor associated antigens derived from cyclin d1
  • Cancer therapy based on tumor associated antigens derived from cyclin d1
  • Cancer therapy based on tumor associated antigens derived from cyclin d1

Examples

Experimental program
Comparison scheme
Effect test

examples

1. Identification and Characterization of Peptides as Used According to the Present Invention

[0093]In general, the peptides as used according to the present invention were identified using the XPRESIDENT® technology as described (see, for example, Weinschenk et al. Integrated Functional Genomics Approach for the Design of Patient-individual Antitumor Vaccines, CANCER RESEARCH 62, 5818-5827, Oct. 15, 2002) on the basis of renal cancer cells. The average overexpression of cyclin D1 (CCND1) in ccRCC against the average expression in normal tissues was 3.0-fold, and 5.7-fold in primary tumors and 5.4-fold in metastases. 55% of primary tumors showed an overexpression against normal kidney.

2. HLA-Restriction of the Peptides as Identified

[0094]For CCN-001 and CCN-002, a good binding to HLA A*02 was predicted using the SYFPEITHI routine (Rammensee et al., 1997; Rammensee et al., 1999). Good binding of CCN-001 to HLA A*0201 was confirmed by an ELISA-based method (Sylvester-Hvid et al., 2002)...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
pharmaceutical compositionaaaaaaaaaa
lengthaaaaaaaaaa
timeaaaaaaaaaa
Login to view more

Abstract

The present invention relates to cyclin D1-derived peptides for use in the improved treatment of cancer in a patient, particularly in the form of a combination therapy using a vaccine. Other aspects relate to the use of the peptides or a combination thereof as a diagnostic tool.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application claims priority to Great Britain Patent Application Number GB1009222.9, filed on Jun. 2, 2010, and U.S. Provisional Patent Application No. 61 / 350,731, filed on Jun. 2, 2010, and this application is also related to PCT / EP2011 / 059121 entitled “Improved cancer therapy based on tumor associated antigens derived from cyclin D1”, the entire contents of which are all the above mentioned documents are hereby incorporated by reference in their entireties.BACKGROUND OF THE INVENTION[0002]1. Field of the Invention[0003]The present invention relates to cyclin-derived peptides for use in the improved treatment of cancer in a patient, particularly in the form of a combination therapy using a vaccine. Other aspects relate to the use of the peptides or a combination thereof as a diagnostic tool.[0004]2. Background of the Invention[0005]Stimulation of an immune response is dependent upon the presence of antigens recognized as foreign by t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/10C07K7/08A61K38/08A61K39/00A61P35/02C12N5/0783A61K49/00C07K7/06A61P35/00
CPCA61K38/2013C12N5/0638A61K38/21A61K39/0011A61K45/06C07K14/4738G01N2800/24G01N2800/7028A61K38/2026A61K39/39A61K38/20A61K31/675A61K38/193A61K38/1709A61K31/404A61K31/44A61K2300/00A61P35/00A61P35/02A61P43/00A61K39/001149A61K38/04C07K7/06
Inventor SINGH, HARPREETWEINSCHENK, TONIWALTER, STEFFEN
Owner IMMATICS BIOTECHNOLOGIES GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap